Major advances not only for ALS but other neurodegenerative diseases
If positive, MIROCALS will be offering a new therapeutic strategy with a high potential to generate major advances in clinical practice for ALS and for other chronic neurodegenerative diseases.
Even if low-dose IL-2 does not slow down the progression of ALS, the project will deliver many new insights into the disease, and make a major contribution to improving future trials in ALS and other neurodegenerative disorders.

Early exclusion of candidate strategies unlikely to succeed
The biomarker analysis will provide fundamental new insights on the usefulness and validity of surrogate markers for clinical endpoints, help uncover reasons for drug unresponsiveness, and assess whether the therapeutic strategy is still worth pursuing.

 

Improving therapeutic outcomes for major chronic health issues with significant impact on disease burden both for individual patients and for health care systems
As stated by the Council of the European Union, “An estimated 8.6 million people in Europe suffer from neurodegenerative diseases” and therapeutic progress for these major health issues has been poor. MIROCALS will contribute to the improvement of therapeutic outcomes for these highly disabling and life threatening diseases by promoting, via our new drug development scheme, the necessary conditions for improved efficiency in clinical drug development.

 

Innovation capacity and integration of new knowledge
MIROCALS will deliver the proof of concept that targeting neuro-inflammation has a significant impact on disease progression with one such disease, ALS, together with the relevant analytical mechanistic determinants predicting a treatment response on neuronal damage that could immediately be used and translated to other neurodegenerative diseases, and potential new targets for new drug developments.
By delivering these innovations to market, MIROCALS will no doubt strengthen the competitiveness and growth of the major players in the neurodegenerative disorders market.

 

Societal environmental and public health impacts
This disease has a major impact on patients since it interferes with all aspects of life and is often disrupting for the affected subject but also for the whole family and social structure around the patient. We firmly believe that by building on a strong model of ALS pathogenesis, we are proposing a sound approach towards effective interventions in ALS.
The proposed clinical trial, designed to demonstrate efficacy, should prove the potential of low dose IL-2 as a treatment aimed at stopping neuronal damage. Its success will be a major breakthrough for the treatment of ALS.

 

Overall, MIROCALS will advance science in the field of ALS and more globally of neurodegenerative disorders, contribute to the development of novel therapeutic interventions, strengthen the competitiveness of European research, boost the European innovative capacity and reduce health care costs, ultimately benefiting patients and society as a whole.

 

News

MIROCALS 1st General Assembly meeting in Brighton, June 9 & 10th 2016

This meeting gathered all MIROCALS partners for presenting the progress made since the launch of the project a year ago as well as the next achievements for the coming year. 

First participant recruited to MIROCALS trial

The MIROCALS consortium is delighted to announce that the first participant has been recruited to the MIROCALS trial, at Hospices Civils de Lyon, France.

Read more.

MIROCALS kick-off meeting in Paris, September 17-18th 2015

This meeting gathered all MIROCALS partners for fine-tuning the planned work programme, in the presence of the EC project officer, and members of the Independent Scientific Advisory Board of the project.

europe

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.